Cyclandelate

Structural formula
Structural formula without stereochemistry
General
Non-proprietary name	Cyclandelate
other names	(3,3,5-trimethylcyclohexyl) -2-hydroxy-2-phenyl acetate ( IUPAC )
Molecular formula	C 17 H 24 O 3
Brief description	white, amorphous solid
External identifiers / databases
CAS number 456-59-7 (mixture of stereoisomers) EC number 207-271-6 ECHA InfoCard 100.006.611 PubChem 2893 DrugBank DB04838 Wikidata Q1147309
Drug information
ATC code	C04 AX01
Drug class	Antidementia drugs
Mechanism of action	Vasodilators
properties
Molar mass	276.37 g · mol -1
Physical state	firmly
Melting point	55-56.5 ° C
boiling point	192-194 ° C (1.82 kPa)
Sublimation point	20 ° C
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS labeling of hazardous substances Caution H and P phrases H: 319 P: ?
Toxicological data	5000 mg kg −1 ( LD 50 ,  rat ,  oral )
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Cyclandelate is a drug that is used to treat cerebral and peripheral circulatory disorders . The antidementia “inhibits the influx of calcium from the blood into the red blood cells ( erythrocytes ), into the blood platelets ( thrombocytes ) and into the vascular wall muscles”. The drug acts as a vasodilator ( vasodilator ) by directly on the smooth muscle of blood vessels acts and can relax the vessel wall. Furthermore, the flow properties of the blood are improved by an increase in the elasticity of the red blood cells and also a decrease in the tendency of the blood platelets to clump and thus also a reduction in clot formation.

Cyclandelate can be used, among other things, to treat dementia ( nootropic ) and for interval therapy in migraines .

It was available in Switzerland under the trade name Cyclandelat Streuli until mid-2013, when the manufacturer stopped production. In Germany, Cyclandelat was withdrawn from the market on May 31, 2008 because the "fictitious approval of Natil capsules " was no longer valid and they were therefore no longer marketable . The reason given by the German manufacturer hotline at the time is the high costs of an approval extension as part of the approval process and for the required clinical tests .

Individual evidence

1. ↑ ^{a b c d} Entry on cyclandelate. In: Römpp Online . Georg Thieme Verlag, accessed on May 30, 2014.
2. ^ The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 452, ISBN 978-0-911910-00-1 .
3. ↑ There is not yet a harmonized classification for this substance . A labeling of cyclandelates in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), which was accessed on December 28, 2019, is shown, which is derived from a self-classification by the distributor .
4. ↑ How cyclandelate works
5. ↑ Page no longer available , search in web archives: product range card (PDF; 532 kB)
6. ↑ DrugBase Online for Natil capsules

literature

• Andreas Ruß: Medicines pocket 2008 . 13th edition. Börm Bruckmeier, Grünwald 2007, p. 235.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !